SCHEMBL25324983

SCHEMBL25324983

O=C(N1CC2(CC(c3nnc(C4(O)CC4)[nH]3)C2)C1)N1CC2(C1)CN(S(=O)(=O)c1cccc(OC(F)(F)F)c1)C2

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AKR1C3 P42330 1/20 0.39
▸ MGLL Q99685 5/20 0.39
▸ ABHD6 Q9BV23 3/20 0.39
▸ SCN9A Q15858 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KDM2B Q8NHM5 1/20 0.34
▸ PKLR P30613 1/20 0.34
▸ CACNA1B Q00975 3/20 0.33
▸ ENPP2 Q13822 2/20 0.33
▸ ATXN2 Q99700 2/20 0.33
▸ CYP11B1 P15538 1/20 0.33
▸ CYP11B2 P19099 1/20 0.33
▸ CYP3A4 P08684 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ NAMPT P43490 1/20 0.32
▸ LIPE Q05469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25326017 0.90 MEN1 (0.40) AKR1C3MEN1KMT2AENPP2ATXN2
SCHEMBL25327398 0.89 AKR1C3 (0.44) AKR1C3MGLLABHD6SCN9AKMT2A
SCHEMBL25324441 0.88 AKR1C3 (0.42) AKR1C3MGLLABHD6SCN9AMEN1
SCHEMBL25325415 0.88 CACNA1B (0.42) AKR1C3MGLLABHD6MEN1KMT2A
SCHEMBL25325438 0.84 CHRM1 (0.40) AKR1C3MGLLABHD6KDM2BPKLR
SCHEMBL25326001 0.82 GAA (0.35) AKR1C3MGLLMEN1KMT2A
SCHEMBL27246280 0.80 AKR1C3 (0.39) AKR1C3MGLLABHD6SCN9AMEN1
SCHEMBL25325553 0.79 KMT2A (0.39) AKR1C3MEN1KMT2A
SCHEMBL25325330 0.79 DPP4 (0.42) AKR1C3MEN1KMT2AENPP2ATXN2
SCHEMBL25325495 0.78 MGLL (0.40) AKR1C3MGLLABHD6SCN9AKDM2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US claimed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP claimed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 AKR1C3 257/4885MGLL 3523/4885ABHD6 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback